BSX Looks 55.4% Undervalued on GF Value™ Amid Device Recall Concerns

gurufocus.com · 2026-08-26

On August 26, 2026, Boston Scientific Corp (NYSE: BSX) disclosed a voluntary recall of certain percutaneous catheter devices, including the ENROUTE Transcarotid

TickrTrends take: Boston Scientific Corporation trades at a significant discount to its GF Value assessment, suggesting the market has priced in considerable risk from recent device recall concerns. For valuation-focused investors, the key question becomes whether the company's underlying business fundamentals and long-term market position justify this discount or whether additional safety-related headwinds could pressure the stock further. The healthcare device sector often experiences temporary valuation dislocations following safety issues, making the sustainability of BSX's current discount an important metric to monitor alongside any regulatory developments and management guidance updates.

Read the full story at gurufocus.com →